Ocrelizumab: Phase III data

The double-blind, double-dummy, international Phase III OPERA II in 835 RRMS patients showed that 300 mg IV ocrelizumab on day 1 and 15 of the first 24-week cycle followed by 600 mg ocrelizumab on day...